Boehringer seeks EU approval for asthma drug

11/15/2013 | Pharmaceutical Business Review Online

A marketing authorization application was filed by Boehringer Ingelheim in Europe for Spiriva Respimat, or tiotropium, as a treatment for asthma patients 18 and older. The application is based on late-stage trial results involving more than 4,000 patients in over 150 locations worldwide.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX